S. 139: Ensuring Access to Clinical Trials Act of 2015


Jan 8, 2015
114th Congress, 2015–2017


Enacted — Signed by the President on Oct 7, 2015

This bill was enacted after being signed by the President on October 7, 2015.


Pub.L. 114-63


Ron Wyden

Senior Senator from Oregon



Read Text »
Last Updated: Sep 30, 2015
Length: 1 pages

About the bill

Full Title

A bill to permanently allow an exclusion under the Supplemental Security Income program and the Medicaid program for compensation provided to individuals who participate in clinical trials for rare diseases or conditions.


There are 30 million Americans living with what S. 139 calls “rare diseases or conditions.” It is difficult enough facing such disorders, but it can be even more difficult finding those willing to participate in clinical trials to provide information, treat and perhaps even cure these conditions. The definition of “rare disease” in the U.S. is “any disease or ...

Read more >


Jan 8, 2015

This is the first step in the legislative process.

Jul 16, 2015
Passed Senate

The bill was passed in a vote in the Senate. It goes to the House next. The vote was by Unanimous Consent so no record of individual votes was made.

Sep 28, 2015
Passed House

The bill was passed by both chambers in identical form. It goes to the President next who may sign or veto the bill. The vote was by voice vote so no record of individual votes was made.

Oct 7, 2015
Enacted — Signed by the President

The President signed the bill and it became law.

This page is about a bill in the United States Congress. A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Links & tools

Primary Source


Congress.gov is updated generally one day after events occur. Legislative activity since the last update may not be reflected on GovTrack. Data via congress project.


Click a format for a citation suggestion: